Patents by Inventor Michael Allen Collingwood
Michael Allen Collingwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932667Abstract: Described herein are methods for the expression and purification of Cas13a and methods for detecting target RNA using Cas13a.Type: GrantFiled: February 25, 2021Date of Patent: March 19, 2024Assignee: INTEGRATED DNNA TECHNOLOGIES INC.Inventors: Sarah Franz Beaudoin, Michael Allen Collingwood, Christopher Anthony Vakulskas, Mark Aaron Behlke
-
Patent number: 11913014Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: February 7, 2022Date of Patent: February 27, 2024Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Publication number: 20240059747Abstract: The present invention pertains to a tag-free CM1 polypeptide and methods for improving homology directed repair (HDR) in a recipient cell using the same. Preferred donor template delivery vehicles include Adeno virus-associated vectors for delivering donor templates, and a preferred tag-free CM1 polypeptide called CM1tf. Isolated nucleic acids encoding tag-free CM1 polypeptides are also provided.Type: ApplicationFiled: August 15, 2023Publication date: February 22, 2024Inventors: Steve Ehren Glenn, Michael Allen Collingwood, Christopher Anthony Vakulskas
-
Publication number: 20230133277Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: ApplicationFiled: July 21, 2022Publication date: May 4, 2023Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Publication number: 20230138679Abstract: The present disclosure concerns polynucleotides and amino acids of Acidaminococcus sp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.Type: ApplicationFiled: July 26, 2022Publication date: May 4, 2023Inventors: Liyang Zhang, Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Kristin Renee Beltz, Mark Aaron Behlke
-
Publication number: 20230049003Abstract: This invention pertains to optimized protein fusion linkers for creating multi-functional chimeric proteins and methods of using the same. Additionally, the invention pertains to chimeric proteins for use in guided endonuclease systems.Type: ApplicationFiled: April 20, 2021Publication date: February 16, 2023Inventors: Michael Allen Collingwood, Steve Ehren Glenn, Christopher Anthony Vakulskas
-
Publication number: 20230040148Abstract: This invention pertains to mutant Lachnospiraceae bacterium ND2006 (Lb) Cas12a nucleic acids and proteins for use in CRISPR/Cas12a endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant LbCas12a protein, wherein the isolated mutant LbCas12a protein is active in a CRISPR/Cas12a endonuclease system. The invention also includes isolated nucleic acids encoding mutant LbCas12a proteins, ribonucleoprotein complexes and CRISPR/Cas12a endonuclease systems having mutant LbCas12a proteins.Type: ApplicationFiled: February 21, 2020Publication date: February 9, 2023Inventors: Sarah Franz BEAUDOIN, Michael Allen COLLINGWOOD, Christopher Anthony VAKULSKAS
-
Publication number: 20220340931Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: ApplicationFiled: February 7, 2022Publication date: October 27, 2022Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Patent number: 11459559Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.Type: GrantFiled: October 21, 2016Date of Patent: October 4, 2022Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
-
Patent number: 11447758Abstract: The present disclosure concerns polynucleotides and amino acids of Acidaminococcus sp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.Type: GrantFiled: August 8, 2019Date of Patent: September 20, 2022Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Liyang Zhang, Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Kristin Renee Beltz, Mark Aaron Behlke
-
Patent number: 11427818Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: July 17, 2020Date of Patent: August 30, 2022Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Patent number: 11242542Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRISPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: April 26, 2018Date of Patent: February 8, 2022Assignee: Integrated DNA Technologies, Inc.Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Publication number: 20220002693Abstract: This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR/Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR/Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.Type: ApplicationFiled: September 8, 2021Publication date: January 6, 2022Inventors: Mark Aaron Behlke, Michael Allen Collingwood, Rolf Turk, Christopher Anthony Vakulskas
-
Patent number: 11136567Abstract: This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR/Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR/Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.Type: GrantFiled: November 22, 2017Date of Patent: October 5, 2021Assignee: Integrated DNA Technologies, Inc.Inventors: Mark Aaron Behlke, Michael Allen Collingwood, Rolf Turk, Christopher Anthony Vakulskas
-
Publication number: 20210062187Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: ApplicationFiled: July 17, 2020Publication date: March 4, 2021Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Patent number: 10767176Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.Type: GrantFiled: October 21, 2016Date of Patent: September 8, 2020Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
-
Patent number: 10717978Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRSPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: GrantFiled: October 10, 2017Date of Patent: July 21, 2020Assignee: INTEGRATED DNA TECHNOLOGIES, INC.Inventors: Christopher Anthony Vakulskas, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke
-
Publication number: 20200216825Abstract: This invention pertains to mutant Cas12a nucleic acids and proteins for use in CRISPR/Cas2a endonuclease systems, and their methods of use. IN particular, the invention pertains to an isolated mutant Cas12a protein, wherein the isolated mutant Cas12a protein is active in a CRISPR/Cas12a endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas12a proteins, ribonucleoprotein complexes and CRISPR/Cas12a endonuclease systems having mutant Cast12a proteins.Type: ApplicationFiled: January 7, 2020Publication date: July 9, 2020Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Sarah Beaudoin
-
Publication number: 20200109382Abstract: The present disclosure concerns polynucleotides and amino acids of Acidaminococcus sp. Cas12a (Cpf1) and methods for their use for genome editing in eukaryotic cells.Type: ApplicationFiled: August 8, 2019Publication date: April 9, 2020Inventors: Liyang Zhang, Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Kristin Renee Beltz, Mark Aaron Behlke
-
Publication number: 20180320201Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRISPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.Type: ApplicationFiled: April 26, 2018Publication date: November 8, 2018Inventors: Christopher Anthony Vakulskas, Nicole Mary Bode, Michael Allen Collingwood, Garrett Richard Rettig, Mark Aaron Behlke